Evelo Biosciences Inc

NASDAQ:EVLOUnited States

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing an orally delivered investigational medicines that acts on cells in the small intestine to produce therapeutic effects throughout the body. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are orally delivered pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles. Its product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Its other product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease. It has developed an integrated platform namely, SINTAX Medicine Platform, which is designed to identify individual strains of microbes capable of modulating the immune system by acting on SINTAX when administered at pharmacologically active doses and appropriately formulated.

Contact Information

Headquarters

620 MEMORIAL DRIVE SUITE 500CAMBRIDGE, MA, United States 02139

Phone

617-577-0300

Fax

302-655-5049

Executives

President, Chief Executive Officer, Director

Balkrishan Gill

Chief Financial Officer, Treasurer

Marella Thorell

Chief Scientific Officer, President of Research and Development

Mark Bodmer

General Counsel, Secretary

Daniel Char

Chief Medical Officer

Duncan McHale